The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Proton beam therapy (PBT) and concurrent chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) for locally advanced non-small cell lung cancer (NSCLC).
 
Seiji Niho
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Hisamitsu Pharmaceutical; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Lilly (Inst); Pfizer (Inst)
 
Atsushi Motegi
No Relationships to Disclose
 
Keisuke Kirita
No Relationships to Disclose
 
Shigeki Umemura
Honoraria - Boehringer Ingelheim
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); MSD (Inst)
 
Shingo Matsumoto
Honoraria - Chugai Pharma; Lilly
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly (Inst); Novartis (Inst); Takeda (Inst)
 
Hironobu Ohmatsu
No Relationships to Disclose
 
Masamichi Toshima
No Relationships to Disclose
 
Satoko Arahira
No Relationships to Disclose
 
Masakatsu Onozawa
No Relationships to Disclose
 
Koichi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Oxonc (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
 
Tetsuo Akimoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Merck Serono; Sumitomo Group; Taiho Pharmaceutical; Zeria Pharmaceutical